Tech player febit axes 60% of staff in restructuring

With a new focus on blood-based microRNA biomarker discovery, Germany's febit has triggered a restructuring that includes axing more than half its workforce and the departure of its CEO. The biomarker company says that 60 percent of its staff has been let go, and CEO Cord F. Staehler has resigned and joined Siemens Healthcare. Hartmut Voss, Ph.D., has joined febit as the new co-CEO with Jochen Kohlhaas who will also continue as febit's CFO. "The restructuring will allow febit to focus on its...